Insulin in a Pill
A drugmaker is testing an alternative to diabetes injections, but many sizable hurdles remain.
Late last year, Denmark-based Novo Nordisk quietly started phase 1 clinical trials of a pill that it hopes to market as an alternative to insulin injections. Offering patients with diabetes the chance to avoid painful needles has long been the holy grail of some pharmaceutical companies, especially Novo, a leader in diabetes treatment for much of its 87-year history. Novo’s entry into clinical testing puts the company ahead of the pack of drugmakers trying to encapsulate insulin into an easy-to-swallow dose.
The fact that Novo entered phase 1 testing with little fanfare is apropos, however, considering the checkered history of insulin drug development. Insulin is a protein that rapidly degrades in the stomach and upper portion of the small intestine, making it almost impossible to deliver orally. Several drugmakers have attempted to deliver insulin via the lungs, most notably Pfizer, which introduced its inhalable insulin drug, Exubera, in 2006. But the product flopped–patients balked at the clumsy inhaler and doctors questioned whether it might endanger the lungs. Several other drugmakers, Novo among them, abandoned their attempts to make inhalable insulin in the wake of Exubera’s failure.
Theoretically, delivering insulin through the stomach should be ideal: insulin would travel directly to the liver, its primary site of action, in a way that mimics the action of endogenous insulin. Because insulin injections go into muscle and fat, patients who use them are susceptible to hypoglycemia. Mads Krogsgaard Thomsen, Novo’s chief scientific officer, says that’s why he believes oral insulin could be safer and more convenient than either the injectable or inhalable forms. But he urges caution for now.
The challenge of making an insulin pill that can survive the digestive system has been magnified by the characteristics of the molecule itself. Human insulin is a large and complex protein. So even if it survives being doused by stomach acid, it’s unlikely to be easily absorbed by the epithelial cells of the gut. Thus the portion of oral insulin that actually makes it into the bloodstream is under 1 percent. “You can’t use human insulin” in a pill, Thomsen says. “It doesn’t work.”
So Novo’s scientists set out to increase the oral viability of insulin tenfold through protein engineering. They embarked on a painstaking, multiyear process designed to answer some key questions: What are the enzymes that attack the molecule, and where do they attack it? The scientists used the insight they gained to design a pill that can transverse the stomach without being broken down, facilitating the transfer of insulin across cells and into the bloodstream.
The drug, called NN1952, will be tested in 150 volunteers over more than a year. The company will examine how the drug is metabolized in patients with Type 1 or Type 2 diabetes, and in healthy people.
Some doctors say they’ll need to see the data before they can get excited about oral insulin. One issue with past attempts was that the pills were affected by food in unexpected ways, says Howard Wolpert, a senior physician at the Joslin Diabetes Center in Boston. “The data from the tests would look okay, and then you’d give it with meals and find the absorption was affected,” says Wolpert, who is not participating in the Novo trials. “Getting the insulin absorption to match the carbohydrate absorption creates a confounding variable.”
Novo’s phase 1 program will include food-interaction studies, Thomsen says. Still, the extent to which oral insulin might be able to replace injections is not yet known: The company will test the drug at various doses, with or without meals, and compare it with both injections and placebos. Thomsen believes oral insulin may prove to be most appealing to Type 2 diabetics, who aren’t dependent on insulin injections because their pancreases are still able to make the protein. Should those patients need an extra boost, however, they may prefer to get it from something other than a needle. “There’s a difference between taking a tablet a day and an injection a day,” he says.
Other companies are experimenting with different delivery methods for insulin. Generex Biotechnology of Worcester, MA, is in late-stage testing of an insulin spray that’s absorbed through the back of the throat. And MannKind of Valencia, CA, is awaiting a verdict from the U.S. Food and Drug Administration on its insulin inhaler.
Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation, says the onus will be on all of these companies to prove that the insulin drugs they deliver mark an improvement over what diabetics are injecting today. “We are tremendously interested in insulins that are safer, more efficacious, faster-acting, and compatible with other medications,” Dutta says. “If they come orally, that would be icing on the cake.”
Learn today what the rest of the world won’t know until tomorrow, at Business of Blockchain 2019.Register now